Clinical Trial Detail

NCT ID NCT01665768
Title Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

lymphoma

Therapies

Rituximab

Everolimus

Age Groups: adult

No variant requirements are available.